Results

Total Results: 2,208 records

Showing results for "drug".

401. Evidence Report on the (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/atypical-antipsychotics-off-label-update_research-protocol.pdf
     May 19, 2010 - Objectives for the Systematic Review Atypical antipsychotics are approved by the United States Food and Drug … To arrive at a quantitative measure, we will use the Jadad scale, which was developed for drug trials2 … The evidence of risks (adverse events) will be summarized within drug (each atypical antipsychotic separately … severely symptomatic persons have higher scores, a negative effect size indicates that the atypical drug

402. Assessing Applicability: Interactive Case Study Quiz (ppt file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/assessing-applicability-quiz.ppt
     September 02, 2013 - The impact of a drug on bone mineral density in young, male, well-trained astronauts in outer space may … The impact of a drug on bone mineral density in young, male, well-trained astronauts in outer space may … The impact of a drug on bone mineral density in young, male, well-trained astronauts in outer space may … The impact of a drug on bone mineral density in young, male, well-trained astronauts in outer space may

403. Assessing Applicability: Interactive Case Study Quiz (ppt file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/assessing-applicability-quiz.ppt
     September 02, 2013 - The impact of a drug on bone mineral density in young, male, well-trained astronauts in outer space may … The impact of a drug on bone mineral density in young, male, well-trained astronauts in outer space may … The impact of a drug on bone mineral density in young, male, well-trained astronauts in outer space may … The impact of a drug on bone mineral density in young, male, well-trained astronauts in outer space may

404. Cer-238-Cervical-Ripening-Appendix-E-1 (xls file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/cer-238-cervical-ripening-appendix-e-1.xlsx
     January 01, 2009 - Inpatient: After administration of the study drug a further minimum of 20 minutes or more of electronic … Outpatient: After administration of the study drug patients underwent 40 minutes of electronic fetal … After administration of study drug, all patients underwent continuous FHR monitoring for 3 hours. … There is no mention of fetal monitoring following the administration of the study drug. … Placebo (Provider NR) -See protocol for intervention 1 NA NA All patients Four hours after the drug

405. Treatments for Schizophrenia in Adults: A Systematic (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/executive-summary-2017-schizophrenia-adult.pdf
     January 01, 2017 - Both groups (treatment and usual care) received usual care, including drug treatment throughout the … Randomized controlled trials were evaluated with criteria developed by the Drug Effectiveness Review … Overall, no drug intervention had high-strength evidence for any outcome of interest, but we found … Among illicit drug users, differences between older SGAs were not found in rate or time to drug discontinuation … Methods for the drug effectiveness review project.

406. App-D-Opioid-Chronic-Pain-Surveillance-Report-2 (xls file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/app-d-opioid-chronic-pain-surveillance-report-2.xlsx
     September 30, 2015 - the trial did not indicate clear differences between treatments for pain, functioning, depression, or drug … Excluded patients with history of psychosis Substance use: Excluded patients with history of illicit drug … stroke, and intracranial hemorrhage), major depression, cancer, and those without previous related drug … applicable; NR = not reported; NRS = numeric rating scale; NSAID = non-steroidal anti-inflammatory drug … ; OAT = opioid agonist therapy; OR = odds ratio; OUD = opioid use disorder; PDMP = prescription drug

407. Horizon Scanning Protocol and Operations Manual January 2013 Revision (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/ahrq-healthcare-horizon-scan-protocol-operations-manual_130826.pdf
     August 01, 2013 - Is this a new molecular entity (drug), biologic, or device being developed for potential diffusion into … Is it subject to approval under FDA’s Investigational New Drug, Biologics Licensing, combination- product … Is it a generic drug? If so, do not select, because these are “me-too” of existing drugs. … Does this appear to be a different/off-label use of an available drug, biologic, or device? … Is this a different delivery mode for an existing drug or device?

408. Horizon-Scan Research-Protocol (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/horizon-scan_research-protocol.pdf
     December 01, 2011 - Is this a new molecular entity (drug), biologic, or generic formulation of a drug being developed for … Is it a generic drug? If so, do not select, because these are “me-too” of existing drugs. … Does this appear to be a different/off-label use of a currently available drug, biologic, or device? … Is this a different delivery mode for an existing drug or device? … Potential Device/Drug Cost Per Patient (if applicable) 12.

409. Interventions for Adults With Serious Mental Illness Who Are Involved With the Criminal Justice System | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/mental-illness-adults-prisons/research-protocol
     December 01, 2019 - National Household Survey on Drug Abuse. The NHSDA report: serious mental illness among adults. … Drug therapy/ Exp antidepressive agents/ Psychotropic drugs/ Therapeutic use.fs. … EMBASE Drug therapy.fs. … counseling Drug therapy Drug treatment/s Drug-based Incarceration-based drug treatment … therapy/ OR drug therapy.fs.

410. Maternal and Fetal Effects of Mental Health Treatments in Pregnant and Breastfeeding Women: A Systematic Review of Pharmacological Interventions | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/mental-health-pregnancy/protocol
     January 01, 2020 - Designing drug trials: considerations for pregnant women. … Food and Drug Administration. … Pharmacoepidemiol Drug Saf. 2013 Sep;22(9):1013-8. doi: 10.1002/pds.3495. PMID: 23893932. … Allergies" OR "Drug Dependency" OR "drug effects" OR "Drug Sensitivity" OR harm* OR harms OR "Long Term … Therapy"[Mesh] OR "drug therapy"[Subheading] OR drug*[tiab] OR pharmacotherap*[tiab] OR pharmacologic

411. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/breast-cancer-medications_disposition-comments.pdf
     March 10, 2010 - Although any synthetic drug can be labeled "chemotherapy" in general, medical, and oncologic parlance … The statement that tamoxifen is the only drug evaluated in premenopausal women has been added to this … US, was minimally evaluated and the major study cited was stopped for an excess of strokes on the drug … Results I like the consistent presentation of results by drug (tam vs. ralox, tam vs. … We assumed that women take the drug for 5 years and NNT estimates were calculated for a 5-year period

412. Hepatitis-C-Screening Executive (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/hepatitis-c-screening_executive.pdf
     November 01, 2012 - The strongest risk factor for HCV infection is injection drug use. … The prevalence of HCV infection in injection drug users varies widely depending on age, duration of … injection drug use, and other factors (such as availability and use of needle exchange programs).15 … Prevalences range from less than 50 percent in more recent studies of younger injection drug users … Drug Alcohol Depend. 2009;105(1-2):160-3. PMID: 19647375. 80.

413. Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Review | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/prostatic-hyperplasia-medications/research
     December 01, 2019 - Skip to main content An official website of the Department of Health & Human Services Careers Contact Us Español FAQs Effective Health Care Program Powered by the Evidence-based Practice Centers …

414. The American College of Chest Physicians (ACCP) proposes to update the medical therapies section of 2007 updated publication on Medical Therapies for Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines.1 1.… | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/get-involved/nominated-topics/the-american-college-of-chest-physicians-accp-proposes-to-update-the-medical-therapies-section-of-2007-updated-publication-on-medical-therapies-for-pulmonary-arterial-hypertension-accp-evidence-based-clinical-practice-guidel
     November 01, 2017 - Appropriateness for EHC Program Does your question include a health care drug, intervention, device

415. Arthritis and Nontraumatic Joint Disease (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/arthritis_hi_impact.pdf
     January 01, 2014 - Ann estimated 750,000 gout patients initiate uric acid-lowering drug therapy in the U.S. annually. … The drug is a genetically engineered form of recombinant porcine urate oxidase, an enzyme not found …  Key Expert Comments: Overall, experts thought that the drug might address the unmet need for a … Nat Rev Drug Discov 2009 Sep;8(9):688. PMID: 19721439 79. Helms S, Darbishire PL. … Positive phase III results for benlysta as lupus drug. Immunotherapy 2009 Sep;1(5):729. 85.

416. Urinary-Incontinence-Treatment Executive (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/urinary-incontinence-treatment_executive.pdf
     April 01, 2012 - The drug needed to be given to eight older patients to achieve more than a 50 percent reduction in … Observational economic drug evaluations29,30 have demonstrated greater absolute rates of treatment … We concluded that there was a low risk of bias in the drug studies. … and nonpharmacological treatment modalities are superior to mono-drug therapy. … Drug Saf. 2001;24(9):703-13. PMID 11522122. 25. Wang PS, Levin R, Zhao SZ, et al.

417. Disposition of Comments Report for Biologic and Nonbiologic Systemic Agents and Phottherapy for Treatment of Chronic Plaque Psoriasis (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/psoriasis-chronic_disposition-comments.pdf
     November 27, 2012 - Food and Drug Administration (FDA) can be included as per AHRQ. … Alefacept is no longer available; Astellas pulled the drug from the market in December 2011. … Although alefacept was voluntarily withdrawn from the market by the manufacturer this year, the drug … For inclusion/exclusion criteria, were data obtained from drug manufacturers? … Food and Drug Administration (FDA) for psoriasis treatment.”

418. Diabetes Mellitus (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/diabetes-horizon-scan-high-impact-1512.pdf
     December 01, 2015 - Food and Drug Administration (FDA) in the first half of 2016. … Afrezza is also listed as a tier 5 drug in some state Medicare drug plan formularies, which is the … Food and Drug Administration (FDA); 2012 Aug 3 [accessed 2012 Jun 18]. [2 p]. … Food and Drug Administration (FDA); 2014 Jun 27 [accessed 2015 Jan 23]. [5 p]. … Food and Drug Administration (FDA); 2014 Jun 30 [accessed 2015 Feb 09]. [5 p].

419. #06 Developmental Delays ADHD, and Autism (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/06_devdelays_potential_high_impact_2012-12-10.pdf
     January 01, 2012 - similar drugs in the same class are read separately), and then topics in the same class of a device, drug … This drug is being investigated for off-label use.

420. Diabetes Mellitus (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/diabetes-horizon-scan-high-impact-1406.pdf
     September 26, 2014 - The drug-device combination has been approved in Europe. … Food and Drug Administration (FDA). … Food and Drug Administration (FDA); 2012 Nov 9. 63 p. … Food and Drug Administration (FDA). … Autoimmune Drug Focus; 2012 Oct 22. 1 p. 56.